Controlled trial of the antigonadotropin danazol in painful nodular benign breast disease.
In a double-blind crossover study of the effects of the antigonadotropin danazol on pain and nodularity in 28 women with cyclical mastalgia danazol was given at doses of 200 mg/day and 400 mg/day, and the responses were assessed both subjectively and objectively. Danazol caused a significant and progressive decrease in breast pain and nodularity when compared with placebo. Symptoms responded more quickly with the 400 mg/day dose of danazol than with the 200 mg dose, but the larger dose also caused greater side-effects. Danazol is a useful addition to the range of antihormones that can be used to suppress the symptoms of severe hormone-related benign breast disease.
D000328:Adult; D001941:Breast Diseases / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003613:Danazol / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006062:Gonadotropins / Q000037:antagonists & inhibitors*; D006801:Humans; D010146:Pain / Q000188:drug therapy*; D011245:Pregnadienes / Q000627:therapeutic use*; D011897:Random Allocation
D006062:Gonadotropins; D011245:Pregnadienes; D003613:Danazol